Pompe Disease with a Late Onset. What Does a Practitioner Need to Know About?
The article presents a clinical case of observation and treatment of a patient with late-onset Pompe disease (LОPD), a rare hereditary storage disease associated with a deficiency of the enzyme acid maltase (acid α-glucosidase) in lysosomes. The first signs of the disease in patient S. – recurrent abdominal pain – appeared at the age of 10. The diagnosis of late-onset Pompe disease was made in one of the federal centers after careful laboratory and molecular genetic studies. Enzyme replacement therapy with Alglucosidase Alpha gave positive results: the patient's condition stabilized, the activity of a number of indicators decreased – aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK). The presented proven clinical case of late-onset Pompe disease with an assessment of the patient’s condition before treatment and the results after enzyme replacement therapy can be useful in the practical work of a wide range of doctors - internists, gastroenterologists, neurologists, general practitioners, etc.
Vishnevskij V.I., Ternovykh T.V., Melnikova E.A. 2024. Pompe Disease with a Late Onset. What Does a Practitioner Need to Know About? Challenges in Modern Medicine, 47(1): 5–13 (in Russian). DOI: 10.52575/2687-0940-2024-47-1-5-13
While nobody left any comments to this publication.
You can be first.
Kurbatov S.A., Nikitin S.S., Zaharova E.Yu. 2015. Bolezn' Pompe s pozdnim nachalom c fenotipom poyasno-konechnostnoj miodistrofii [Late-Onset Pompe Disease with Girdle-Bone Myodystrophy Phenotype]. Nervno-myshechnye bolezni 5(3): 62–8. doi: 10.17650/2222-8721-2015-5-3-6268.Sun A. 2018. Lysosomal storage disease overview. Ann Transl Med. 6:476. doi: 10.21037/atm.2018.11.39
Sun A. 2018. Lysosomal Storage Disease Overview. Ann Transl Med. 6: 476. doi: 10.21037/atm.2018.11.39
de Araujo M.E., Liebscher G., Hess M.W., Huber L.A. 2020. Lysosomal Size Matters. Traffic.; 21: 60–75. doi: 10.1111/tra.12714
Heffner G., James L., Chaivorapol C. 2018. A Novel Hybrid Promote Directing AAV-Mediated Expression of Acid Alpha-Glucosidase to Liver, Muscle and CNS Yields Optimized Outcomes in a Mouse Model of Pompe Disease. Neuromuscular Disord. 28: S135-6.
Martina J.A., Raben N., Puertollano R. 2020. Lysosomal Storage Diseases. Cell. 180:602–02.e1. doi: 10.1016/j.cell.2020.01.017
Pena L.D., Barohn R., Byrne B. 2019. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of the Novel Enzyme Replacement Therapy Avalglucosidase Alfa (neoGAA) in Treatment-Naïve and Alglucosidase Alfa-Treated Patients with Late-Onset Pompe Disease: A Phase 1, Open-Label, Multicenter, Multinational, Ascending Dose Study; 29: 167–86. doi: 10.1016/j.nmd.2018.12.004
Clemens P., Mozaffar T., Schoser B. 2019. Safety and Efficacy of Advanced and Targeted Acid α-glucosidase (AT-GAA)(ATB200/AT2221) in ERT-switch Nonambulatory Patients with Pompe Disease: Preliminary Results from the ATB200-02 Trial. Mol. Genet. Metab. 126: S40-1. doi:10.1016/j.ymgme.2018.12.084
Kishnani P., Schoser B., Bratkovic D. 2019. First-in-human Study of Advanced and Targeted Acid α-glucosidase (AT-GAA) (ATB200/AT2221) in Patients with Pompe Disease: Preliminary Functional Assessment Results from the ATB200-02 Trial. Mol. Genet. Metab. 126: S86. doi:10.1016/j.ymgme.2018.12.212
Hardcastle N., Boulis N.M., Federici T. 2018. AAV Gene Delivery to the Spinal Cord: Serotypes, Methods, Candidate Diseases, and Clinical Trials. Expert Opin. Biol. Ther. 18: 293–307. doi: 10.1080/14712598.2018.1416089
Keeler A.M., Zieger M., Todeasa S.H. 2019. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease. Hum Gene Ther 30: 57–68. doi: 10.1089/hum.2018.016
Kohler L., Puertollano R., Raben N. 2018. Pompe Disease: From Basic Science to Therapy. Neurotherapeutics 15: 928–42 doi: 10.1007/s13311-018-0655-y
Mayeuf-Louchart A., Lancel S., Sebti Y., Pourcet B., Loyens A., Delhaye S., Duhem C., Beauchamp J., Ferri L., Thorel Q., Boulinguiez A., Zecchin M., Dubois-Chevalier J. 2019. Glycogen Dynamics Drives Lipid Droplet Biogenesis During Brown Adipocyte Differentiation. Cell Rep.; 29: 1410–18. e6. doi: 10.1016/j.celrep.2019.09.073
Gupta N., Kazi Z.B., Nampoothiri S., Jagdeesh S., Kabra M., Puri R.D., Muranjan M., Kalaivani M., Rehder C., Bali D., Verma I.C., Kishnani P.S. 2020. Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease. J Pediatr. 216: 44–50. e5. doi: 10.1016/j.jpeds.2019.08.058
Ellingwood S.S., Cheng A. 2018. Biochemical and clinical aspects of glycogen storage diseases. J. Endocrinol. Sep; 238(3): R131-R141, doi: 10.1530/JOE-18-0120
Reuser A.J., van der Ploeg A.T., Chien Y.H., Llerena J. Jr., Abbott M.A., Clemens P.R., Kimonis V.E., Leslie N., Maruti S.S., Sanson B.J., Araujo R., Periquet M., Toscano A. 2019. GAA Variants and Phenotypes Among 1,079 Patients with Pompe Disease: Data from the Pompe Registry. 40: 2146–64. doi: 10.1002/humu.23878
Skurat A.V., Segvich D.M., De Paoli-Roach A.A., Roach P.J. 2017. Novel Method for Detection of Glycogen in Cells. Glycobiology; 27(5): 416–424. doi: 10.1093/glycob/cwx005
Rodrigues G.A., Shalaev E., Karami T.K. 2018. Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye. Pharm. Res. 36: 29. doi: 10.1007/s11095-018-2554-7
Boentert M., Prigent H., Várdi K. 2016. Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe disease. Int. J. Mol. Sci. 17: 1–17. doi: 10.3390/ijms17101735
Chan J., Kazi Z.B., Desai A.K. 2017. The Emerging Phenotype of Late-Onset Pompe Disease: a Systematic Literature Review. Mol. Genet. Metab; 120(3): 163–72. doi: 10.1016/ j.ymgme. 2016.12.004.
Park H., Kim J., Lee Y.K. 2018. Four Unreported Types of Glycans Containing Mannose-6-Phosphate are Heterogeneously Attached at Three Sites (Including Newly Found Asn 233) to Recombinant Human Acid Alpha-Glucosidase that is the Only Approved Treatment for Pompe Disease. Biochem. Biophys. Res. Commun. 495: 2418–24. doi: 10.1016/j.bbrc.2017.12.101
Poelman E., Hoogeveen-Westerveld M., Kroos-de Haan M.A. 2018. High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy. J. Pediatr. 195: 236–43. e3. doi: 10.1016/j.jpeds.2017.11.046
Toscano A., Rodolico C., Musumeci O. 2019. Multisystem Late Onset Pompe Disease (LOPD): an Update on Clinical Aspects. 7: 284. doi: 10.21037/atm.2019.07.24
Tarallo A., Carissimo A., Gatto F., Nusco E., Toscano A., Musumeci O., Coletta M., Karali M., Acampora E., Damiano C., Minopoli N., Fecarotta S., Della Casa R. 2019. MicroRNAs as Biomarkers in Pompe Disease. Genet Med. 21: 591–600. doi: 10.1038/s41436-018-0103-8
The work was carried out without external sources of funding.